The current role of anti-emetic drugs in oncology: a recent revolution in patient symptom control
- 30 June 1991
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 18 (2) , 95-135
- https://doi.org/10.1016/0305-7372(91)90009-o
Abstract
No abstract availableThis publication has 142 references indexed in Scilit:
- Making Chemotherapy EasierNew England Journal of Medicine, 1990
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and VomitingNew England Journal of Medicine, 1990
- Lorazepam for the control of chemotherapy-related nausea and vomiting in childrenThe Journal of Pediatrics, 1988
- Metoclopramide as an Antiemetic in ChemotherapyNew England Journal of Medicine, 1982
- Emesis as a Critical Problem in ChemotherapyNew England Journal of Medicine, 1981
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981
- Levonantradol for Chemotherapy‐Induced Emesis: Phase I—II Oral AdministrationThe Journal of Clinical Pharmacology, 1981
- Antiemetic Effect of Intramuscular Levonantradol in Patients Receiving Anticancer ChemotherapyThe Journal of Clinical Pharmacology, 1981
- Clinical Experience with Levonantradol Hydrochloride in the Prevention of Cancer Chemotherapy-Induced Nausea and VomitingThe Journal of Clinical Pharmacology, 1981